Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

NICE has said the Alzheimer's disease drug is too expensive to be available on the NHS, but researchers are now hoping to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

If I were a statistician tucked away in an NHS backroom, I might well curse the day the health service was founded. There, on ...

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

The Dementia Trials Accelerator (DTA) – which will be spearheaded by the UK Dementia Research Institute (UK DRI) and Health ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

It is the second Alzheimer’s drug to receive such a mixed reception within months. In August, the U.K. regulator authorized Leqembi while the same watchdog agency issued draft guidance recommending ...